Mandate

Vinge represents Apax Partners LLP in connection with the acquisition of stakes in Unilabs

December 16, 2016 M&A

Vinge, together with Simpson Thacher & Bartlett LLP, represents Apax Partners LLP in connection with the divestment by private equity funds Nordic Capital Fund VI and Apax France VII of their respective stakes in Unilabs to Apax IX, advised by Apax Partners LLP.

Unilabs is with over 5,300 employees and 112 laboratories one of Europe’s leading medical diagnostics businesses. Unilabs generated annual revenues of €673 million in 2015.

The transaction is subject to regulatory approvals and the financial terms of the transaction are not being disclosed.

The Vinge team includes partner Jonas Johansson together with, among others, Alex Miler and Rasmus Perdahl.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026